A biopharmaceutical company, which is engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
The market blinked a little at SciClone's recent earnings, likely due to a downtick in revenues from recently acquired subsidiary NovaMed. I'm not sure what this signifies, although I have noticed a lot of cyclicity in revenues from pharmas based in China. What I do like about SciClone is that they've been solidly profitable for the last three quarters and they're using profits to build a stronger cash position. Since dilution seems to be a much more prevalent source of pipeline funding in the baby biotech sector, profitability always gets my attention. The remnants of SciClone's pipeline seem to have died out so a new acquisition is a substantial possiblity.